Total thyroidectomy (Tx) versus thionamides (antithyroid drugs) in patients with moderate-to-severe Graves' ophthalmopathy - a 1-year follow-up: study protocol for a randomized controlled trial

Trials
Lindsay BrammenAndrea Papp

Abstract

Graves' disease (GD) is characterized by thyrotoxicosis and goiter and arises through circulating autoantibodies that bind to, and stimulate, the thyroid hormone receptor (TSHR). A temporal relation between the onset of hyperthyroidism and the onset of ophthalmopathy, a common extrathyroidal manifestation, has been demonstrated. Graves' ophthalmopathy (GO) is typically characterized by an inflammation and expansion of the extraocular muscles and an increase in retroorbital fat. There are currently three forms of therapies offered for hyperthyroidism caused by Graves' disease: antithyroid drugs (ATD) (thionamides), radioiodine ablation (RAI) and thyroidectomy (Tx). To date, there is no clear recommendation on the treatment of Graves' disease and GO, mainly due to the individuality of the disease in each patient. The aim of the study is to examine the difference in the outcome of GO in patients with moderate-to-severe GO who receive Tx versus further ATD after suffering their first relapse of GO, or in which GO stays the same following the initial decrease in ATD therapy after 6 months. This prospective randomized clinical trial with observer-blinded analysis will analyze 60 patients with moderate-to-severe GO who receive Tx vers...Continue Reading

References

Jun 25, 1992·The New England Journal of Medicine·L TallstedtA Taube
Jan 1, 1992·Thyroid : Official Journal of the American Thyroid Association·C MarcocciA Pinchera
Apr 1, 1967·The Journal of Clinical Endocrinology and Metabolism·J P KrissR Utiger
Nov 11, 1993·The New England Journal of Medicine·R S Bahn, A E Heufelder
Jun 1, 1997·Thyroid : Official Journal of the American Thyroid Association·P VittiA Pinchera
Jan 8, 1998·The New England Journal of Medicine·L BartalenaA Pinchera
Apr 22, 1999·Thyroid : Official Journal of the American Thyroid Association·Q Y Duh
Jul 10, 2003·Autoimmunity Reviews·Glinda S Cooper, Berrit C Stroehla
Jul 21, 2005·Thyroid : Official Journal of the American Thyroid Association·Geeta LalOrlo H Clark
Feb 27, 2008·European Journal of Endocrinology·Luigi BartalenaUNKNOWN European Group on Graves' Orbitopathy (EUGOGO)
Mar 11, 2008·World Journal of Surgery·Peter StålbergPer Hellman
Mar 18, 2008·Thyroid : Official Journal of the American Thyroid Association·Luigi BartalenaWilmar M Wiersinga
Apr 24, 2008·Clinical Endocrinology·Shamasunder H AcharyaPrakash Abraham
Feb 10, 2009·World Journal of Surgery·Yasser A ElsayedHosam A-F Halim
Mar 31, 2009·Endocrinology and Metabolism Clinics of North America·Laszlo Hegedüs
Jun 29, 2010·Thyroid : Official Journal of the American Thyroid Association·Katharina A PontoGeorge J Kahaly
Jan 18, 2011·The Journal of Clinical Endocrinology and Metabolism·S ZangG J Kahaly
May 29, 2012·Best Practice & Research. Clinical Endocrinology & Metabolism·Laszlo HegedüsThomas H Brix
Jan 16, 2014·Autoimmunity Reviews·Francesca MenconiMichele Marinò
May 2, 2014·European Thyroid Journal·Luigi Bartalena

❮ Previous
Next ❯

Citations

Jul 18, 2019·Current Opinion in Ophthalmology·Jonathan C P Roos, Rachna Murthy
Jul 16, 2021·Therapeutic Advances in Ophthalmology·Clara J MenSara T Wester

❮ Previous
Next ❯

Software Mentioned

Randomizer for Clinical Trials
nQuery Advisor
SPSS ( Statistical Package for Social Sciences

Related Concepts

Related Feeds

Ataxia telangiectasia (MDS)

Ataxia telangiectasia is a rare neurodegenerative diseases caused by defects in the ATM gene, which is involved in DNA damage recognition and repair pathways. Here is the latest research on this autosomal recessive disease.